Seeking Alpha

Vanda Pharmaceuticals (VNDA) will pay Eli Lilly (LLY) up to $100M for exclusive rights to...

Vanda Pharmaceuticals (VNDA) will pay Eli Lilly (LLY) up to $100M for exclusive rights to develop a drug that has shown promise as a treatment for alcohol addiction. The company calls the licensing of VLY-686 "an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs."
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs